STAAR Surgical (NASDAQ:STAA) Receives Average Recommendation of “Hold” from Brokerages

STAAR Surgical (NASDAQ:STAA) has earned an average rating of “Hold” from the eleven analysts that are presently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $47.00.

STAA has been the topic of several research analyst reports. Stifel Nicolaus reissued a “buy” rating and issued a $50.00 price objective on shares of STAAR Surgical in a research report on Monday, April 1st. BTIG Research upgraded STAAR Surgical from a “neutral” rating to a “buy” rating and set a $46.00 price objective on the stock in a research note on Tuesday, June 11th. Mizuho boosted their target price on STAAR Surgical from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 8th. Piper Sandler boosted their target price on STAAR Surgical from $33.00 to $40.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 8th. Finally, William Blair upgraded STAAR Surgical from a “market perform” rating to an “outperform” rating in a research report on Thursday, April 4th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Clear Street Markets LLC purchased a new stake in STAAR Surgical during the 3rd quarter valued at $29,000. Cape Investment Advisory Inc. purchased a new stake in shares of STAAR Surgical in the fourth quarter worth $42,000. GAMMA Investing LLC raised its position in shares of STAAR Surgical by 313.9% during the 1st quarter. GAMMA Investing LLC now owns 1,308 shares of the medical instruments supplier’s stock valued at $50,000 after purchasing an additional 992 shares during the period. Covestor Ltd lifted its stake in shares of STAAR Surgical by 82,466.7% during the 3rd quarter. Covestor Ltd now owns 2,477 shares of the medical instruments supplier’s stock valued at $100,000 after buying an additional 2,474 shares in the last quarter. Finally, Quest Partners LLC purchased a new position in shares of STAAR Surgical during the 4th quarter valued at $146,000. Institutional investors own 96.70% of the company’s stock.

STAAR Surgical Stock Performance

Shares of STAAR Surgical stock opened at $41.23 on Thursday. STAAR Surgical has a 52 week low of $26.66 and a 52 week high of $58.82. The stock has a 50 day moving average price of $43.68 and a two-hundred day moving average price of $37.01. The stock has a market capitalization of $2.03 billion, a PE ratio of 133.00 and a beta of 0.65.

STAAR Surgical (NASDAQ:STAA) last announced its quarterly earnings data on Tuesday, May 7th. The medical instruments supplier reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.12). STAAR Surgical had a net margin of 4.69% and a return on equity of 6.83%. The firm had revenue of $77.40 million during the quarter, compared to analyst estimates of $75.34 million. During the same period last year, the business posted $0.05 EPS. The company’s revenue was up 5.3% on a year-over-year basis. Research analysts forecast that STAAR Surgical will post 0.09 EPS for the current year.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.